Warning letter
Profounda, Inc.: warning letter of Feb 1, 2023
FDA warning letter 642595 · Division of Pharmaceutical Quality Operations II
Key facts
| Reference number | 642595 |
|---|---|
| Company | Profounda, Inc. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Feb 1, 2023 |
| Posted date | Mar 14, 2023 |
| Issuing office | Division of Pharmaceutical Quality Operations II |
| Product type | Drugs |
| CFR sections cited | 211.166(a), 211.63, 211.100(a), 211.160(b), 211.165(b), 211.84(a), 211.34 |
| Inspection city | Orlando |
| Inspection ZIP | 32824 |
| Inspection start date | Aug 3, 2022 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: